

RSK1 (RPS6KA1) Antibody (S363) Blocking peptide
Synthetic peptide
Catalog # BP7941d**Specification**

RSK1 (RPS6KA1) Antibody (S363) Blocking peptide - Product InformationPrimary Accession [Q15418](#)**RSK1 (RPS6KA1) Antibody (S363) Blocking peptide - Additional Information****Gene ID** 6195**Other Names**

Ribosomal protein S6 kinase alpha-1, S6K-alpha-1, 90 kDa ribosomal protein S6 kinase 1, p90-RSK 1, p90RSK1, p90S6K, MAP kinase-activated protein kinase 1a, MAPK-activated protein kinase 1a, MAPKAP kinase 1a, MAPKAPK-1a, Ribosomal S6 kinase 1, RSK-1, RPS6KA1, MAPKAPK1A, RSK1

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP7941d](/product/products/AP7941d) was selected from the S363 region of human RPS6KA1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

RSK1 (RPS6KA1) Antibody (S363) Blocking peptide - Protein Information**Name** RPS6KA1**Synonyms** MAPKAPK1A, RSK1**Function**

Serine/threonine-protein kinase that acts downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and stress-induced activation of the transcription factors CREB1, ETV1/ER81 and NR4A1/NUR77, regulates translation through RPS6 and EIF4B phosphorylation, and mediates cellular proliferation, survival, and differentiation by modulating mTOR signaling and repressing pro- apoptotic function of BAD and DAPK1 (PubMed:[10679322](http://www.uniprot.org/citations/10679322), PubMed:[16223362](http://www.uniprot.org/citations/16223362), PubMed:[15117958](http://www.uniprot.org/citations/15117958), PubMed:

<http://www.uniprot.org/citations/12213813> target="_blank">12213813, PubMed:9430688, PubMed:17360704, PubMed:26158630, PubMed:18722121, PubMed:35772404). In fibroblast, is required for EGF-stimulated phosphorylation of CREB1, which results in the subsequent transcriptional activation of several immediate-early genes (PubMed:18508509, PubMed:18813292). In response to mitogenic stimulation (EGF and PMA), phosphorylates and activates NR4A1/NUR77 and ETV1/ER81 transcription factors and the cofactor CREBBP (PubMed:12213813, PubMed:16223362). Upon insulin-derived signal, acts indirectly on the transcription regulation of several genes by phosphorylating GSK3B at 'Ser-9' and inhibiting its activity (PubMed:18508509, PubMed:18813292). Phosphorylates RPS6 in response to serum or EGF via an mTOR-independent mechanism and promotes translation initiation by facilitating assembly of the pre-initiation complex (PubMed:17360704). In response to insulin, phosphorylates EIF4B, enhancing EIF4B affinity for the EIF3 complex and stimulating cap- dependent translation (PubMed:16763566). Is involved in the mTOR nutrient-sensing pathway by directly phosphorylating TSC2 at 'Ser- 1798', which potently inhibits TSC2 ability to suppress mTOR signaling, and mediates phosphorylation of RPTOR, which regulates mTORC1 activity and may promote rapamycin-sensitive signaling independently of the PI3K/AKT pathway (PubMed:15342917). Also involved in feedback regulation of mTORC1 and mTORC2 by phosphorylating DEPTOR (PubMed:22017876). Mediates cell survival by phosphorylating the pro- apoptotic proteins BAD and DAPK1 and suppressing their pro-apoptotic function (PubMed:10679322, PubMed:16213824). Promotes the survival of hepatic stellate cells by phosphorylating CEBPB in response to the hepatotoxin carbon tetrachloride (CCl4) (PubMed:11684016). Mediates induction of hepatocyte proliferation by TGFA through phosphorylation of CEBPB (PubMed:18508509, PubMed:18813292). Is involved in cell cycle regulation by phosphorylating the CDK inhibitor CDKN1B, which promotes CDKN1B association with 14-3-3 proteins and prevents its translocation to the nucleus and inhibition of G1 progression (PubMed:18508509, PubMed:18813292). Phosphorylates EPHA2 at 'Ser-897', the RPS6KA-EPHA2 signaling pathway controls cell migration (PubMed:26158630). In response to mTORC1 activation, phosphorylates EIF4B at 'Ser-406' and 'Ser-422' which stimulates bicarbonate cotransporter SLC4A7 mRNA translation, increasing SLC4A7 protein abundance and function (PubMed:35772404).

Cellular Location

Nucleus. Cytoplasm.

RSK1 (RPS6KA1) Antibody (S363) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

RSK1 (RPS6KA1) Antibody (S363) Blocking peptide - Images

RSK1 (RPS6KA1) Antibody (S363) Blocking peptide - Background

RPS6KA1 is a member of the RSK (ribosomal S6 kinase) family of serine/threonine kinases. This kinase contains 2 nonidentical kinase catalytic domains and phosphorylates various substrates, including members of the mitogen-activated kinase (MAPK) signalling pathway. The activity of this protein has been implicated in controlling cell growth and differentiation.

RSK1 (RPS6KA1) Antibody (S363) Blocking peptide - References

Cavet, M.E., et al., J. Biol. Chem. 278(20):18376-18383 (2003).Versteeg, H.H., et al., J. Biol. Chem. 277(30):27065-27072 (2002).Fingar, D.C., et al., Genes Dev. 16(12):1472-1487 (2002).Lu, H., et al., J. Pharmacol. Exp. Ther. 300(3):818-823 (2002).Saitoh, M., et al., J. Biol. Chem. 277(22):20104-20112 (2002).